Pharmaceutical Preparations · VA · CIK 1267565
Develops, licenses, acquires, and commercializes differentiated pharmaceutical products for ADHD and moderate to severe pain
Comparable business profile · signals at a glance
In the 90 days to Mar 18, 2026: 2 sold $2.7M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 18, 2026 | Dieter DavidEVP & General Counsel | Sell | 13,976 | $34.92 | $488K |
| Mar 9, 2026 | Dieter DavidEVP & General Counsel | Sell | 6,224 | $36.65 | $228K |
| Mar 3, 2026 | Dreyer ScottEVP & Chief Commercial Officer | Sell | 46,417 | $40.36 | $1.9M |
| Mar 3, 2026 | Dreyer ScottEVP & Chief Commercial Officer | Sell | 3,559 | $40.99 | $146K |
| Dec 8, 2025 | Dreyer ScottEVP & Chief Commercial Officer | Sell | 11,125 | $47.89 | $533K |
| Dec 8, 2025 | Dreyer ScottEVP & Chief Commercial Officer | Sell | 6,475 | $48.66 | $315K |
| Dec 5, 2025 | Balice-Gordon Rita J.Director | Sell | 3,650 | $47.03 | $172K |
| Nov 12, 2025 | Fallon John A.Director | Sell | 34,853 | $47.21 | $1.6M |
| Nov 6, 2025 | Tupper ColleenEVP & Chief Financial Officer | Sell | 25,142 | $40.38 | $1.0M |
| Nov 6, 2025 | Tupper ColleenEVP & Chief Financial Officer | Sell | 4,858 | $41.28 | $201K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.